查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
嗜铬细胞瘤的全球市场:2022年～2029年
市场调查报告书
商品编码
1082816

嗜铬细胞瘤的全球市场:2022年～2029年

Global Pheochromocytoma Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

本报告提供全球嗜铬细胞瘤的市场调查，彙整市场定义和概要，新型冠状病毒感染疾病 (COVID-19) 以及其他的市场影响因素的分析，未满足需求，市场规模的转变·预测，各种区分·地区/各主要国家的明细，竞争环境，主要企业简介等资讯。

目录

第1章 调查手法·调查范围

第2章 界市场定义和概要

第3章 摘要整理

第4章 市场动态

  • 影响市场的要素
    • 促进因素
    • 阻碍因素
    • 市场机会
    • 影响分析

第5章 产业分析

  • 波特的五力分析
  • 价格分析
  • 未满足需求

第6章 COVID-19分析

  • COVID-19:对市场的影响分析
  • COVID-19风暴中的价格动态
  • 供需频谱
  • 政府在COVID-19疫情下的市场相关措施
  • 製造商的策略性举措
  • 总论

第7章 市场分析:各诊断

  • 实验室筛检
    • 血液检验
    • 尿液检查
    • 其他
  • 影像检查
    • CT
    • MRI
    • PET
    • 其他
  • 其他

第8章 市场分析:各治疗类型

  • Alpha阻断剂
    • 苯氧苯甲胺盐酸盐（二芐基）
    • 甲磺酸酚妥拉明 (OraVerse)
    • 特拉唑嗪（Hytrin）
    • 甲磺酸多沙唑嗪 (Cardura, Cardura XL)
    • 其他
  • β- 阻断剂
    • 普萘洛尔 (Inderal LA, InnoPran XL)
    • 阿替洛尔（Tenormin）
    • 美托洛尔（Lopressor）
    • 艾司洛尔（Brevibloc）
    • 其他
  • 手术
  • 放射治疗
  • 化疗
  • 其他

第9章 市场分析:各终端用户

  • 医院
  • 诊所
  • 诊断中心
  • 门诊病人手术中心
  • 其他

第10章 市场分析:各流通管道

  • 医院药局
  • 零售药局
  • 线上药局
  • 其他

第11章 市场分析:各地区

  • 北美
  • 欧洲
  • 南美
  • 亚太地区
  • 中东·非洲

第12章 竞争情形

  • 主要的展开·策略
  • 企业占有率分析
  • 产品基准
  • 关注的主要企业清单

第13章 企业简介

  • Septodont
  • Abbott Laboratories
  • Jubilant Cadista Pharmaceuticals Inc.
  • Pfizer Inc.
  • ANI Pharmaceuticals, Inc.
  • WellSpring Pharmaceutical Corporation
  • Valeant Pharmaceuticals North America LLC.
  • Hikma Pharmaceuticals PLC
  • Progenics Pharmaceuticals, Inc.
  • Baxter

第14章 全球嗜铬细胞瘤市场:DataM

简介目录
Product Code: DMPH5226

Market Overview

The global pheochromocytoma market size was valued US$ XX million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of XX % during the forecast period (2022-2029).

Pheochromocytoma is a neuroendocrine tumor that develops from cells known as chromaffin cells. The adrenal glands contain cells that create hormones that the body needs. The adrenal glands are tiny organs that sit on top of the kidneys in the upper abdomen. The tumor releases hormones that may cause high blood pressure, headache, sweating, and panic attack symptoms. If a pheochromocytoma isn't treated, severe or life-threatening damage to other body systems can result. The treatment consists of anti-hypertensives and surgery.

Market Dynamics

Growing clinical trials by the market players for the treatment of pheochromocytoma are expected to drive market growth.

On August 12, 2021, Merck Sharp & Dohme LLC conducted a Phase 2 Study to evaluate the efficacy and safety of Belzutifan (MK-6482, Formerly PT2977) monotherapy in participants with Advanced Pheochromocytoma/Paraganglioma (PPGL) or Pancreatic Neuroendocrine Tumor (pNET). Moreover, National Cancer Institute (NCI), on December 2, 2021, conducted phase II trial tests on whether the combination of talazoparib and temozolomide works to shrink tumors in patients with rare cancer that have spread to other places in the body (advanced). Thus, the market is expected to drive in the forecast period from the above statements.

Restraint:

Stringent government regulations, lack of availability of precise medications, and lack of awareness associated with the disease among people are some factors the market is expected to hamper in the forecast period.

COVID-19 Impact Analysis

The COVID-19 pandemic has moderately impacted healthcare systems and the market. COVID-19 was found in the adrenal and pituitary glands of some patients who died from the disease, indicating that these organs could be among the infection's targets. IV steroid (dexamethasone) supplementation in hospitalized patients requiring oxygen was one of the first highly effective therapy for COVID-19 infection. Moreover, according to a medical study, the adrenal system is one of the most highly affected organ systems in the body during acute active infection in patients with COVID-19 infection who require hospitalization. On the other hand, patients were subjected to significant disruptions in their care, with most appointments and treatments being canceled, curtailed, or postponed. Almost all used telemedicine to replace face-to-face visits, about half of patients undergoing treatment changes switched from hospital to home therapy, and a quarter of patients had difficulty getting their medications.

Additionally, the pandemic interrupts the supply chain and process. Many companies will vary to other geographic regions to ensure that products remain available and protect their supply chain. Thus, from the above statements, the market got affected, and it is expected to gain traction quickly with the resumption of the economic activities.

Segment Analysis

Surgery segment is expected to hold the largest market share in pheochromocytoma market

The surgery segment is expected to dominate in 2021. The primary treatment for a pheochromocytoma is surgery to remove the tumor. Pheochromocytoma is treated by surgically removing the tumor-bearing adrenal gland(s). Except for individuals with significant additional medical concerns that would prevent them from surviving an operation, this is true for practically all patients. Medical treatment can counteract the effects of adrenaline excess, although it is not as successful as surgery. For instance, Adrenalectomy is the removal of one or both adrenal glands. The tissues and lymph nodes inside the belly will be evaluated during this surgery, and if the tumor has spread, these tissues are also removed. Therefore, it has increased the demand for surgery. Thus, the market segment is expected to hold the largest market share in the forecast period from the above statements.

Geographical Analysis

North America region holds the largest market share in the global pheochromocytoma market

In 2021, North America accounted for the highest revenue share. The high prevalence of pheochromocytoma, increasing clinical trials by the market players, rising geriatric population, well-established infrastructure, and advancement in the diagnosis of the diseases are factors the market is expected to boost in the forecast period. For instance, In the USA, the prevalence of pheochromocytoma ranges from 0.2 to 0.8 per 100,000 persons. Moreover, pheochromocytoma in patients with hypertension in general outpatient clinics is about 0.1%. Additionally, pheochromocytoma affects about 5% of patients with adrenal tumors detected by accident on imaging. Individuals with a germline mutation in pheochromocytoma susceptibility genes may have a 50% chance of developing pheochromocytoma. Also, the gene expression profiling of various tumors has provided new subtype-specific options for targeted therapies. Thus, the North American region is expected to hold the largest market share in the forecast period from the above statements.

Competitive Landscape

Major key players in the pheochromocytoma market are Septodont, Abbott Laboratories, Jubilant Cadista Pharmaceuticals Inc., Pfizer Inc., ANI Pharmaceuticals, Inc., WellSpring Pharmaceutical Corporation, Valeant Pharmaceuticals North America LLC. Hikma Pharmaceuticals PLC, Progenics Pharmaceuticals, Inc. and Baxter.

Progenics Pharmaceuticals, Inc.:

Overview:

Progenics Pharmaceuticals, Inc., of Tarrytown, N.Y., is a biopharmaceutical company focused on innovative therapeutics for patients who have cancer and related conditions. The company is focused on the development and commercialization of innovative targeted medicines and artificial intelligence to find, fight and follow cancer, including therapeutic agents designed to treat cancer (AZEDRA, 1095, and PSMA TTC); prostate-specific membrane antigen ("PSMA") targeted imaging agents for prostate cancer (PyL and 1404); and imaging analysis technology (aBSI and PSMA AI).

­Product Portfolio:

AZEDRA (iobenguane I 131): AZEDRA (iobenguane I 131) is a prescription medicine used to treat adult and pediatric patients 12 years and older with cancers known as pheochromocytoma and paraganglioma that are positive for the norepinephrine transporter (as determined by an iobenguane scan), and who require systemic anticancer therapy.

Why Purchase the Report?

Visualize the composition of the pheochromocytoma market segmentation by diagnosis, treatment, end user, distribution channel, and region highlighting the key commercial assets and players.

Identify commercial opportunities in pheochromocytoma market by analyzing trends and co-development deals.

Excel data sheet with thousands of data points of pheochromocytoma market- level 4/5 segmentation.

PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.

Product mapping in excel for the key product of all major market players

The global pheochromocytoma market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.

Target Audience

Service Providers/ Buyers

Industry Investors/Investment Bankers

Education & Research Institutes

Research Professionals

Emerging Companies

Manufacturers

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

  • 3.1. Market Snippet by Diagnosis
  • 3.2. Market Snippet by Treatment
  • 3.3. Market Snippet by End user
  • 3.4. Market Snippet by Distribution channel
  • 3.5. Market Snippet by Region

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Growing clinical trials by the market players for the treatment of pheochromocytoma are expected to drive market growth..
    • 4.1.2. Restraints:
      • 4.1.2.1. Lack of availability of precise medications is expected to hamper in the forecast period.
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Supply Chain Analysis
  • 5.2. Pricing Analysis
  • 5.3. Unmet Needs

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Diagnosis

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
    • 7.1.2. Market Attractiveness Index, By Diagnosis Segment
  • 7.2. Lab Tests*
    • 7.2.1. Blood test
    • 7.2.2. Urine test
    • 7.2.3. Others
    • 7.2.4. Introduction
    • 7.2.5. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Imaging tests
    • 7.3.1. CT
    • 7.3.2. MRI
    • 7.3.3. PET
    • 7.3.4. Others
  • 7.4. Others

8. By Treatment type

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment type
    • 8.1.2. Market Attractiveness Index, By Treatment type Segment
  • 8.2. Alpha-Blockers*
    • 8.2.1. Phenoxybenzamine hydrochloride (Dibenzyline)
    • 8.2.2. Phentolamine mesylate (OraVerse)
    • 8.2.3. Terazosin (Hytrin)
    • 8.2.4. Doxazosin mesylate (Cardura, Cardura XL)
    • 8.2.5. Others
    • 8.2.6. Introduction
    • 8.2.7. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Beta Blockers
    • 8.3.1. Propranolol (Inderal LA, InnoPran XL)
    • 8.3.2. Atenolol (Tenormin)
    • 8.3.3. Metoprolol (Lopressor)
    • 8.3.4. Esmolol (Brevibloc)
    • 8.3.5. Others
  • 8.4. Surgery
  • 8.5. Radiation therapy
  • 8.6. Chemotherapy
  • 8.7. Others

9. By End user

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 9.1.2. Market Attractiveness Index, By End user Segment
  • 9.2. Hospitals*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Clinics
  • 9.4. Diagnostic Centers
  • 9.5. Ambulatory Surgical Centers
  • 9.6. Others

10. By Distribution Channel

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.1.2. Market Attractiveness Index, By Distribution Channel Segment
  • 10.2. Hospital Pharmacies*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 10.3. Retail Pharmacies
  • 10.4. Online Pharmacies
  • 10.5. Others

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
    • 11.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment type
    • 11.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 11.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
    • 11.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment type
    • 11.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 11.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. U.K.
      • 11.3.7.3. France
      • 11.3.7.4. Italy
      • 11.3.7.5. Spain
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
    • 11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment type
    • 11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. Brazil
      • 11.4.7.2. Argentina
      • 11.4.7.3. Rest of South America
  • 11.5. Asia Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
    • 11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment type
    • 11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. China
      • 11.5.7.2. India
      • 11.5.7.3. Japan
      • 11.5.7.4. Australia
      • 11.5.7.5. Rest of Asia Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
    • 11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment type
    • 11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 11.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

12. Competitive Landscape

  • 12.1. Key Developments and Strategies
  • 12.2. Company Share Analysis
  • 12.3. Product Benchmarking
  • 12.4. List of Key Companies to Watch

13. Company Profiles

  • 13.1. Septodont*
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Key Highlights
    • 13.1.4. Financial Overview
  • 13.2. Abbott Laboratories
  • 13.3. Jubilant Cadista Pharmaceuticals Inc.
  • 13.4. Pfizer Inc.
  • 13.5. ANI Pharmaceuticals, Inc.
  • 13.6. WellSpring Pharmaceutical Corporation
  • 13.7. Valeant Pharmaceuticals North America LLC.
  • 13.8. Hikma Pharmaceuticals PLC
  • 13.9. Progenics Pharmaceuticals, Inc.
  • 13.10. Baxter

LIST NOT EXHAUSTIVE

14. Global Pheochromocytoma Market - DataM

  • 14.1. Appendix
  • 14.2. About Us and Applications
  • 14.3. Contact Us